Function of Aurora kinase A in Taxol-resistant breast cancer and its correlation with P-gp

Molecular Medicine Reports

Volumn 4, Issue 4, 2011, Pages 739-746

  Li, Yan ^a   Tang, Ke ^a   Zhang, Haijing ^a   Zhang, Yi ^a   Zhou, Wanqi ^a   Chen, Xiaoguang ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Aurora A; Breast cancer; Chemoresistance; P gp; Taxol

Indexed keywords

AURORA A KINASE; P GP PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL VIABILITY; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOGENE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; P-GLYCOPROTEIN; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS;

EID: 79957652748     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.494     Document Type: Article

References (24)

1. Moulder S and Hortobagyi GN: Advances in the treatment of breast cancer. Clin Pharmacol Ther 83: 26-36, 2008.
2. Newman SP, Foster PA, Stengel C, et al: STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res 14: 597-606, 2008. (Pubitemid 351226130)
3. Patel N, Chatterjee SK, Vrbanac V, et al: Rescue of paclitaxel sensitivity by repression of Prohibitin 1 in drug-resistant cancer cells. Proc Natl Acad Sci USA 107: 2503-2508, 2010.
4. Zhou J, Liu M, Aneja R, Chandra R, Lage H and Joshi HC: Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res 66: 445-452, 2006. (Pubitemid 43166053)
5. Payton M, Bush TL, Chung G, et al: Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res 70: 9846-9854, 2010.
6. Lapenna S and Giordano A: Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566, 2009.
7. Kumano M, Miyake H, Terakawa T, Furukawa J and Fujisawa M: Suppressed tumour growth and enhanced chemosensitivity by RNA interference targeting Aurora-A in the PC3 human prostate cancer model. BJU Int 106: 121-127, 2010.
8. Li Y, Zhang ZF, Chen J, et al: VX680/MK-0457, a potent and selective Aurora kinase inhibitor, targets both tumor and endothelial cells in clear cell renal cell carcinoma. Am J Transl Res 2: 296-308, 2010.
9. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr and Gandara DR: Aurora kinases as anticancer drug targets. Clin Cancer Res 14: 1639-1648, 2008. (Pubitemid 351471713)
10. Katayama H, Brinkley WR and Sen S: The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22: 451-464, 2003. (Pubitemid 36791899)
11. Crosio C, Fimia GM, Loury R, et al: Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol 22: 874-885, 2002. (Pubitemid 34053065)
12. Nobili S, Landini I, Giglioni B and Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7: 861-879, 2006.
13. Guo X, Ma N, Wang J, et al: Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 8: 375, 2008.
14. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234, 2006. (Pubitemid 43336035)
15. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J and Sugimoto Y: Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 6: 2092-2102, 2007. (Pubitemid 47052500)
16. Litman T, Druley TE, Stein WD and Bates SE: From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959, 2001. (Pubitemid 32652819)
17. Han CY, Cho KB, Choi HS, Han HK and Kang KW: Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 29: 1837-1844, 2008.
18. Hua Yang, Lili He, Patricia Kruk, et al: Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells. Int J Cancer 119: 2304-2312, 2006.
19. Ayman El-Sheikh, Rong Fan, Diane Birks, et al: Inhibition of Aurora kinase A enhances chemosensitivity of medulloblastoma cell lines. Pediatr Bloof Cancer 55: 35-41, 2010.
20. Li Y, Li S, Han Y, et al: Calebin-A induces apoptosis and modulates MAPK family activity in drug resistant human gastric cancer cells. Eur J Pharmacol 591: 252-258, 2008.
21. McCubrey JA, Steelman LS, Abrams SL, et al: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46: 249-279, 2006. (Pubitemid 44301348)
22. Anand S, Penrhyn-Lowe S and Venkitaraman AR: Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 3: 51-62, 2003. (Pubitemid 37443890)
23. Hata T, Furukawa T, Sunamura M, et al: RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 65: 2899-2905, 2005. (Pubitemid 40490094)
24. McGrogan BT, Gilmartin B, Carney DN and McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785: 96-132, 2008.